Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.08 (-2.00%)
Close on Nov 13, 2026Market cap $577.02MP/E –Yield –
Aclaris Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Aclaris Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 79.2%. For fiscal 2025 it was 73.3%, against 85.1% the year before. The highest annual figure on record is 89.0% in fiscal 2023.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 73.3% | −11.8 |
| FY2024 | Dec 31, 2024 | 85.1% | −4.0 |
| FY2023 | Dec 31, 2023 | 89.0% | +2.6 |
| FY2022 | Dec 31, 2022 | 86.5% | +56.2 |
| FY2021 | Dec 31, 2021 | 30.3% | +9.5 |
| FY2020 | Dec 31, 2020 | 20.8% | +16.7 |
| FY2019 | Dec 31, 2019 | 4.1% | −48.6 |
| FY2018 | Dec 31, 2018 | 52.7% | +24.4 |
| FY2017 | Dec 31, 2017 | 28.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 87.2% | +3.5 |
| Q2 FY2026 | Jun 30, 2026 | 86.6% | +15.6 |
| Q1 FY2026 | Mar 31, 2026 | 80.2% | +15.0 |
| Q4 FY2025 | Dec 31, 2025 | 58.9% | −33.4 |
| Q3 FY2025 | Sep 30, 2025 | 83.7% | −1.3 |
| Q2 FY2025 | Jun 30, 2025 | 71.0% | −6.4 |
| Q1 FY2025 | Mar 31, 2025 | 65.2% | −1.0 |
| Q4 FY2024 | Dec 31, 2024 | 92.3% | −3.5 |
| Q3 FY2024 | Sep 30, 2024 | 85.0% | −5.9 |
| Q2 FY2024 | Jun 30, 2024 | 77.4% | +33.2 |
| Q1 FY2024 | Mar 31, 2024 | 66.3% | −1.8 |
| Q4 FY2023 | Dec 31, 2023 | 95.9% | +7.2 |
| Q3 FY2023 | Sep 30, 2023 | 90.9% | −4.3 |
| Q2 FY2023 | Jun 30, 2023 | 44.2% | +14.1 |
| Q1 FY2023 | Mar 31, 2023 | 68.0% | +47.5 |
| Q4 FY2022 | Dec 31, 2022 | 88.7% | +65.2 |
| Q3 FY2022 | Sep 30, 2022 | 95.1% | +61.4 |
| Q2 FY2022 | Jun 30, 2022 | 30.1% | −0.7 |
| Q1 FY2022 | Mar 31, 2022 | 20.5% | −11.8 |
| Q4 FY2021 | Dec 31, 2021 | 23.5% | +4.8 |
| Q3 FY2021 | Sep 30, 2021 | 33.8% | +15.8 |
| Q2 FY2021 | Jun 30, 2021 | 30.8% | −1.4 |
| Q1 FY2021 | Mar 31, 2021 | 32.4% | +22.5 |
| Q4 FY2020 | Dec 31, 2020 | 18.6% | +12.4 |
| Q3 FY2020 | Sep 30, 2020 | 17.9% | +2.0 |
| Q2 FY2020 | Jun 30, 2020 | 32.1% | +44.3 |
| Q1 FY2020 | Mar 31, 2020 | 9.8% | +5.4 |
| Q4 FY2019 | Dec 31, 2019 | 6.2% | +1.8 |
| Q3 FY2019 | Sep 30, 2019 | 16.0% | −22.9 |
| Q2 FY2019 | Jun 30, 2019 | -12.2% | −80.1 |
| Q1 FY2019 | Mar 31, 2019 | 4.4% | −9.1 |
| Q4 FY2018 | Dec 31, 2018 | 4.4% | −20.2 |
| Q3 FY2018 | Sep 30, 2018 | 38.9% | +5.1 |
| Q2 FY2018 | Jun 30, 2018 | 67.9% | – |
| Q1 FY2018 | Mar 31, 2018 | 13.5% | – |
| Q4 FY2017 | Dec 31, 2017 | 24.5% | – |
| Q3 FY2017 | Sep 30, 2017 | 33.8% | – |
See a number that looks wrong?